Mason R S, Rohl P G, Lissner D, Posen S
Am J Dis Child. 1982 Oct;136(10):909-13. doi: 10.1001/archpedi.1982.03970460039009.
Vitamin D metabolites were measured in 21 patients with hypophosphatemic osteomalacia of juvenile onset. In eight patients who had not received any antirachitic treatment, serum 25-hydroxyvitamin D(25-OH-D) and 1,25-dihydroxyvitamin D (1,25-[OH]2D) values were normal, whereas serum 24,25-dihydroxyvitamin D (24,25-[OH]2D) values were lower than in normal subjects. In 13 patients who were receiving ergocalciferol and oral elemental phosphorus, serum 25-OH-D and 24,25-(OH)2D concentrations were elevated and serum 1,25-(OH)2D values were low. The findings in untreated patients supported the hypothesis that vitamin D metabolism is abnormal in hypophosphatemic rickets/osteomalacia. The reduction of serum 1,25-(OH)2D levels with ergocalciferol and phosphate therapy gives further support to a therapeutic role for 1,25-(OH)2D in this disorder.
对21例青少年期起病的低磷性骨软化症患者的维生素D代谢产物进行了测定。在8例未接受任何抗佝偻病治疗的患者中，血清25-羟维生素D（25-OH-D）和1,25-二羟维生素D（1,25-[OH]2D）值正常，而血清24,25-二羟维生素D（24,25-[OH]2D）值低于正常受试者。在13例接受麦角钙化醇和口服元素磷治疗的患者中，血清25-OH-D和24,25-(OH)2D浓度升高，血清1,25-(OH)2D值降低。未治疗患者的研究结果支持了低磷性佝偻病/骨软化症中维生素D代谢异常的假说。麦角钙化醇和磷酸盐治疗使血清1,25-(OH)2D水平降低，这进一步支持了1,25-(OH)2D在该疾病中的治疗作用。
